Public Market Listing

SANIONNasdaq Stockholm

Nasdaq Stockholm primary exchange listing

Live quotes, historical charts, and market capitalization for Saniona are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
TesofensineNo recent activity
Phase 3
Noradrenaline/dopamine/serotonin reuptakeSmall molecule
Obesity

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q4$0.5M—$63M$5.0Mreport ↗

Saniona reported revenue of $0.49M, down 98.5% YoY, cash and equivalents of $63.14M, and a quarterly net burn of $4.95M for Q4 2025.

Figures only: this period's report disclosed no narrative text

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$44M—$63M—report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$32M—$28M—report ↗